Does coffee consumption alter plasma lipoprotein(A) concentrations? A systematic review

Coffee consumption alters plasma lipid and cholesterol concentrations, however, its effects on lipoprotein(a) (Lp(a)) have received little study. The aim of this PRISMA compliant systematic review was to examine the role of coffee on serum Lp(a). This study was prospectively registered (PROSPERO 2015:CRD42015032335). PubMed, Scopus, Web of Science and Cochrane Central were searched from inception until 9th January 2016 to detect trials and epidemiological studies investigating the impact of coffee on serum Lp(a) concentrations in humans. We identified six relevant publications describing nine experimental trials of various designs. There were a total of 640 participants across all studies and experimental groups. In short-term controlled studies, consumption of coffee, or coffee diterpenes was associated with either a reduction in serum Lp(a) of 11 mg/dl (6 trials, 275 participants), or no effect (2 trials, 56 participants). Conversely, one cross-sectional study with 309 participants showed serum Lp(a) was elevated in chronic consumers of boiled coffee who had a median Lp(a) of 13.0 mg/dl (range 0-130) compared with consumers of filtered coffee who had median Lp(a) 7.9 mg/dl (range 0-144) The effect of coffee on Lp(a) is complex and may follow a biphasic time-course. The type of coffee and the method of preparation appear to be important to determining the effect on Lp(a

Diet risk behaviors in relation with personality features in students from Timis county, Romania (case-control study)

Universitatea de Medicină şi Farmacie Victor Babeş, Timişoara, România, Conferința științifico-practică cu participare internațională Centrul de Sănătate Publică din municipiul Chișinău – 70 de ani la straja sănătăţii 23 octombrie 2014In the performed study we investigated the existence of a relation between students` personality features and diet risk behaviors. The material was a sample consisted in 2074 students, 62.48 % girls and 37.51 % boys, aged between 18 and 25 years. The method (observational inquiry) consisted in two questionnaire applying: Freiburg Personality Inventory (FPI, 212 items) and CORT 2004 (126 items, from which we selected 11 items (Q100-Q109), that refers to diet behavior. We chose for our study 2 groups of students: group of control – no consumption and group of study – 2 or more times/day consumption of a certain food. Statistical work was realized by the support of SPSS 16 Program. Obtained results: we identified a statistical significant difference between the 2 groups of students (case-control) of sweets consumption for sincerity (χ2=7.997, Sig.0.018) and of fried potatoes consumption for aggressiveness (χ2=6.334, Sig.0.042). A positive correlation was registered between sweets consumption-sincerity (γ=0.342, Sig.0.004), between fried potatoes consumption-aggressiveness (γ=0.373, Sig.0.039) and fried potatoes consumption-domination (γ=0.398, Sig.0.024). In conclusion, there is a positive relation, statistical significant between sweets consumption and sincerity and between fried potatoes consumption and aggressiveness, domination at the investigated student

Role of Natural Products in Ameliorating Drugs and Chemicals Toxicity

Herbal medicines have a long history over than 7000 years in traditional treatment, therapeutic experiences, and clinical trials including Egypt, China, and Korea. This practice is still the mainstay of about 75–80% of the world population, mainly in the developing countries, for primary health care and promotion because of better cultural acceptability, better compatibility with the human body, and lesser side effects. However, the last few years have seen a major increase in their use in the developed world. Nowadays, we can find a bipolarised market for the active ingredients: those chemically produced and mainly supported by the pharmaceutical companies and those natural constituents that are demanded by an increased number of patients. Although natural products have not been always active as supposed, some of them are scientifically recognised as therapeutically active. Indeed, it has to be noted that some drugs, still used in the current therapies, are extracted from plants. Some of these can have additive action if coadministered with synthesized drugs or ameliorate the drug toxicity

The Effects of Cinnamon Supplementation on Plasma Lipid Concentrations: A Systematic Review and Meta-Analysis

Background: Cinnamon is a rich botanical source of polyphenols, whose positive effects on blood lipid concentrations have been hypothesized, but have not been conclusively studied. Objective: To systematically review and evaluate the effect of administration of cinnamon on blood lipid concentrations. Methods: We assessed 13 RCTs with 750 participants investigating the effect of cinnamon supplementation on blood lipid concentrations. A meta-analysis was performed using randomeffect models, with weighted mean differences (with 95% CI) for endpoints calculated using a random-effects model. Results: No statistically significant effect of cinnamon was observed on blood LDL-C (WMD: - 0.16 mmol/L [-6.19 mg/dL], 95% CI: -0.35, 0.03 [-13.53, 1.16], p = 0.10) and HDL-C (WMD: 0.05 mmol/L [1.92 mg/dL], 95% CI: -0.03, 0.12 [-0.03, 4.64], p = 0.21) concentrations. However, a statistically significant reduction in blood triglycerides (WMD: -0.27 mmol/L [- 23.91 mg/dL], 95% CI: -0.39, -0.14 [-34.54, -12.40], p < 0.01) and total cholesterol concentrations (WMD: -0.36 mmol/L [-13.92 mg/dL], 95% CI: -0.63, -0.09 [-24.36, -3.48], p < 0.01) was observed. HDL-C was significantly elevated following the omission of one study (WMD: 0.04 mmol/L [1.54 mg/dL], 95% CI: 0.03, 0.06 [1.16, 2.32], p < 0.01) during our sensitivity analysis. A meta-regression analysis was conducted and no significant association was found between changes in lipid parameters and cinnamon dose. In contrast, changes in blood levels of total cholesterol (slope: 0.09; 95% CI: 0.02, 0.16; p < 0.01), LDL-C (slope: 0.05; 95% CI: 0.001, 0.10; p = 0.05) and triglycerides (slope: 0.06; 95% CI: 0.04, 0.09; p < 0.01) were significantly and positively associated with the duration of supplementation. No statistically significant association was found between blood HDL-C changes and duration of supplementation. Conclusion: Cinnamon supplementation significantly reduced blood triglycerides and total cholesterol concentrations without any significant effect on LDL-C and HDL-C

Impact of statin therapy on coronary plaque composition: A systematic review and meta-analysis of virtual histology intravascular ultrasound studies

Background: Virtual histology intravascular ultrasound (VH-IVUS) imaging is an innovative tool for the morphological evaluation of coronary atherosclerosis. Evidence for the effects of statin therapy on VH-IVUS parameters have been inconclusive. Consequently, we performed a systematic review and meta-analysis to investigate the impact of statin therapy on plaque volume and its composition using VH-IVUS. Methods: The search included PubMed, Cochrane Library, Scopus and Embase (through 30 November 2014) to identify prospective studies investigating the effects of statin therapy on plaque volume and its composition using VH-IVUS. Results: We identified nine studies with 16 statin treatment arms and 830 participants. There was a significant effect of statin therapy in reducing plaque volume (standardized mean difference (SMD): -0.137, 95 % confidence interval (CI): -0.255, -0.019; P = 0.023), external elastic membrane volume (SMD: -0.097, 95 % CI: -0.183, -0.011; P = 0.027) but not lumen volume (SMD: -0.025, 95 % CI: -0.110, +0.061; P = 0.574). There was a significant reduction in fibrous plaque volume (SMD: -0.129, 95 % CI: -0.255, -0.003; P = 0.045) and an increase of dense calcium volume (SMD: +0.229, 95 % CI: +0.008, +0.450

The Effect of Statins on Cardiovascular Outcomes by Smoking Status: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Smoking is an important risk factor for cardiovascular disease (CVD) morbidity and mortality. The impact of statin therapy on CVD risk by smoking status has not been fully investigated. Therefore we assessed the impact of statin therapy on CVD outcomes by smoking status through a systematic review of the literature and meta-analysis of available randomized controlled trials (RCTs). The literature search included EMBASE, ProQuest, CINAHL and PUBMED databases to 30 January 2016 to identify RCTs that investigated the effect of statin therapy on cumulative incidence of major CVD endpoints (e.g. non-fatal myocardial infarction, revascularization, unstable angina, and stroke). Relative risks (RR) ratios were calculated from the number of events in different treatment groups for both smokers and non-smokers. Finally 11 trials with 89,604 individuals were included. The number of smokers and non-smokers in the statin groups of the analyzed studies was 8826 and 36,090, respectively. The RR for major CV events was 0.73 (95% confidence interval [CI]: 0.67-0.81; p<0.001) in nonsmokers and 0.72 (95%CI: 0.64-0.81; p<0.001) in smokers. Moderate to high heterogeneity was observed both in non-smokers (I2=77.1%, p<0.001) and in smokers (I2=51.6%, p=0.024) groups. Smokers seemed to benefit slightly more from statins than non-smokers according to the number needed to treat (NNT) analysis (23.5 vs 26.8) based on RRs applied to the control event rates. The number of avoided events per 1000 individuals was 42.5 (95%CI: 28.9-54.6) in smokers and 37.3 (95%CI: 27.2-46.4) in non-smokers. In conclusion, this meta-analysis suggests that the effect of statins on CVD is similar for smokers and non-smokers, but in terms of NNTs and number of avoided events, smokers seem to benefit more although non-significantly

Efficacy of Statin Therapy in Pulmonary Arterial Hypertension : a Systematic Review and Meta-Analysis

Since the evidence regarding statin therapy in PAH has not been conclusive, we assessed the impact of statin therapy in PAH through a systematic review and meta-analysis of available studies. We searched selected databases up to August 1, 2015 to identify the studies investigating the effect of statin administration on PAH. Meta-analysis was performed using either a fixed-effects or random-effect model according to I 2 statistic. Meta-analysis of 8 studies with 665 patients did not suggest any significant improvement in 6-min walking distance (6MWD) by statin therapy (weighed mean difference [WMD]:-6.08 m, 95% confidence interval [CI]:-25.66, 13.50, p = 0.543; Q = 8.41, I 2 = 28.64%). Likewise, none of the other indices including pulmonary arterial pressure (WMD:-0.97 mmHg, 95%CI:-4.39, 2.44, p = 0.577; Q = 14.64, I 2 = 79.51%), right atrial pressure (WMD: 1.01 mmHg, 95%CI:-0.93, 2.96, p = 0.307; Q = 44.88, I2 = 95.54%), cardiac index (WMD: 0.05 L/min/m2, 95%CI:-0.05, 0.15, p = 0.323; Q = 3.82, I 2 = 21.42%), and pulmonary vascular resistance (WMD:-1.42 dyn 17s/cm5, 95%CI:-72.11, 69.27, p = 0.969; Q = 0.69, I2 = 0%) was significantly altered by statin therapy. In conclusion, the results of the meta-analysis did not show a statistically significant effect of statin therapy in the improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, cardiac index and pulmonary vascular resistance